Cartesian Therapeutics Stock Gains on Full-Year Revenue Beat

Dow Jones

Mar 10

By Elias Schisgall

Shares of Cartesian Therapeutics rose after the company reported 2025 revenue ahead of Wall Street expectations despite widening its loss for the year.

Shares were up 29% to $8.81 in Monday afternoon trading. The stock has fallen 51% over the past year.

The biotechnology company reported a full-year loss of $130.3 million, or $5.02 a share, compared with a loss of $77.4 million, or $4.49 a share, a year earlier.

Revenue fell to $2.8 million from $38.9 million. Collaboration and licensing revenue fell to $400,000 from $38.3 million, partially offset by a rise in grant revenues to $2.4 million from $638,000.

Analysts were expecting a loss of $2.35 a share and $2 million in revenue.

The company said it remains on track to deliver on its Phase 3 trial for Descartes-08, a T-cell therapy, to treat myasthenia gravis, a chronic autoimmune disease leading to muscle weakness.

It added that is working to a launch a Phase 2 trial for Descartes-08 to treat myositis, a form of chronic muscle inflammation, within the first half of the year.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

March 09, 2026 13:51 ET (17:51 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2618675097"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618675097\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618675097?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 01:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618675097","market":"sg","top_or_hot":-1,"title":"Cartesian Therapeutics Stock Gains on Full-Year Revenue Beat","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/RNAC\">Cartesian Therapeutics</a> rose after the company reported 2025 revenue ahead of Wall Street expectations despite widening its loss for the year. \n</p>\n<p>\n  Shares were up 29% to $8.81 in Monday afternoon trading. The stock has fallen 51% over the past year. \n</p>\n<p>\n  The biotechnology company reported a full-year loss of $130.3 million, or $5.02 a share, compared with a loss of $77.4 million, or $4.49 a share, a year earlier. \n</p>\n<p>\n  Revenue fell to $2.8 million from $38.9 million. Collaboration and licensing revenue fell to $400,000 from $38.3 million, partially offset by a rise in grant revenues to $2.4 million from $638,000. \n</p>\n<p>\n  Analysts were expecting a loss of $2.35 a share and $2 million in revenue. \n</p>\n<p>\n  The company said it remains on track to deliver on its Phase 3 trial for Descartes-08, a T-cell therapy, to treat myasthenia gravis, a chronic autoimmune disease leading to muscle weakness. \n</p>\n<p>\n  It added that is working to a launch a Phase 2 trial for Descartes-08 to treat myositis, a form of chronic muscle inflammation, within the first half of the year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 09, 2026 13:51 ET (17:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cartesian Therapeutics Stock Gains on Full-Year Revenue Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCartesian Therapeutics Stock Gains on Full-Year Revenue Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-10 01:51</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/RNAC\">Cartesian Therapeutics</a> rose after the company reported 2025 revenue ahead of Wall Street expectations despite widening its loss for the year. \n</p>\n<p>\n  Shares were up 29% to $8.81 in Monday afternoon trading. The stock has fallen 51% over the past year. \n</p>\n<p>\n  The biotechnology company reported a full-year loss of $130.3 million, or $5.02 a share, compared with a loss of $77.4 million, or $4.49 a share, a year earlier. \n</p>\n<p>\n  Revenue fell to $2.8 million from $38.9 million. Collaboration and licensing revenue fell to $400,000 from $38.3 million, partially offset by a rise in grant revenues to $2.4 million from $638,000. \n</p>\n<p>\n  Analysts were expecting a loss of $2.35 a share and $2 million in revenue. \n</p>\n<p>\n  The company said it remains on track to deliver on its Phase 3 trial for Descartes-08, a T-cell therapy, to treat myasthenia gravis, a chronic autoimmune disease leading to muscle weakness. \n</p>\n<p>\n  It added that is working to a launch a Phase 2 trial for Descartes-08 to treat myositis, a form of chronic muscle inflammation, within the first half of the year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 09, 2026 13:51 ET (17:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RNAC","symbol_name":"Cartesian Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2618675097","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618675097","pubTimestamp":1773078660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Cartesian Therapeutics rose after the company reported 2025 revenue ahead of Wall Street expectations despite widening its loss for the year.Shares were up 29% to $8.81 in Monday afternoon trading. The stock has fallen 51% over the past year.The biotechnology company reported a full-year loss of $130.3 million, or $5.02 a share, compared with a loss of $77.4 million, or $4.49 a share, a year earlier.Revenue fell to $2.8 million from $38.9 million. Collaboration and licensing revenue fell to $400,000 from $38.3 million, partially offset by a rise in grant revenues to $2.4 million from $638,000.Analysts were expecting a loss of $2.35 a share and $2 million in revenue.The company said it remains on track to deliver on its Phase 3 trial for Descartes-08, a T-cell therapy, to treat myasthenia gravis, a chronic autoimmune disease leading to muscle weakness.It added that is working to a launch a Phase 2 trial for Descartes-08 to treat myositis, a form of chronic muscle inflammation,","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"RNAC":"Cartesian Therapeutics"},"translate_title":"Cartesian Therapeutics股价因全年收入超出预期而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNAC":1.5},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Shares of Cartesian Therapeutics rose after the company reported 2025 revenue ahead of Wall Street expectations despite widening its loss for the year. \n\n\n  Shares were up 29% to $8.81 in Monday afternoon trading. The stock has fallen 51% over the past year. \n\n\n  The biotechnology company reported a full-year loss of $130.3 million, or $5.02 a share, compared with a loss of $77.4 million, or $4.49 a share, a year earlier. \n\n\n  Revenue fell to $2.8 million from $38.9 million. Collaboration and licensing revenue fell to $400,000 from $38.3 million, partially offset by a rise in grant revenues to $2.4 million from $638,000. \n\n\n  Analysts were expecting a loss of $2.35 a share and $2 million in revenue. \n\n\n  The company said it remains on track to deliver on its Phase 3 trial for Descartes-08, a T-cell therapy, to treat myasthenia gravis, a chronic autoimmune disease leading to muscle weakness. \n\n\n  It added that is working to a launch a Phase 2 trial for Descartes-08 to treat myositis, a form of chronic muscle inflammation, within the first half of the year. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 09, 2026 13:51 ET (17:51 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}